Why TC Biopharm (TCBP) Stock Is Down Over 60% Today

TC Biopharm PLC – ADR TCBP shares are trading lower by 62% to 58 cents during Friday’s session after the company announced the transition from Nasdaq to OTC markets.

What To Know: TC BioPharm a clinical-stage biotech firm, announced that Nasdaq has decided to delist its securities for failing to meet the $1.00 minimum bid price requirement under Rule 5550(a)(2).

The company received notice of this decision on Thursday. TC BioPharm, which focuses on allogeneic gamma-delta T-cell therapies for cancer and other diseases, is now working on an appeal to Nasdaq in an effort to regain compliance.

Read Also: ‘Monster Equity Inflows Say No One Really Believes Trade War,’ Bank Of America’s Hartnett Says

According to data from Benzinga Pro, has a 52-week high of $523.20 and a 52-week low of $0.54.